Related Experiment Video
Updated: Mar 16, 2026

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
Published on: October 27, 2023
Utilizing national and international registries to enhance pre-market medical device regulatory evaluation
Lilly Q Yue1, Gregory Campbell1, Nelson Lu1
1a Division of Biostatistics , Center for Devices and Radiological Health, U.S. Food and Drug Administration , Silver Spring , Maryland , USA.
Abstract:
Regulatory decisions are made based on the assessment of risk and benefit of medical devices at the time of pre-market approval and subsequently, when post-market risk-benefit balance needs reevaluation. Such assessments depend on scientific evidence obtained from pre-market studies, post-approval studies, post-market surveillance studies, patient perspective information, as well as other real world data such as national and international registries. Such registries provide real world evidence and are playing a more and more important role in enhancing the safety and effectiveness evaluation of medical devices. While these registries provide large quantities of data reflecting real world practice and can potentially reduce the cost of clinical trials, challenges arise concerning (1) data quality adequate for regulatory decision-making, (2) bias introduced at every stage and aspect of study, (3) scientific validity of study designs, and (4) reliability and interpretability of study results. This article will discuss related statistical and regulatory challenges and opportunities with examples encountered in medical device regulatory reviews.
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioequivalence studies: Biowaivers
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
In Vitro Drug Release Testing: Overview, Development and Validation

